Calling All Innovators: FDA And CMS Seek Candidates For Parallel Review Pilot
This article was originally published in The Gray Sheet
FDA and CMS are seeking device companies with innovative technologies to participate in the first test of "parallel," or simultaneous, pre-market approval and Medicare coverage reviews.
You may also be interested in...
The device center is in the very early stages of launching the “CDRH Reimbursement Program,” planning to go beyond its current parallel-review collaboration with CMS to work with device firms, CMS and private payers to streamline the pathway from market approval to reimbursement.
While speaking Sept. 24 at the 2013 AdvaMed conference, CMS Administrator Marilyn Tavenner outlined CMS’ priorities over the next three years, focusing on access, quality and cost with a specific emphasis on CMS collaborations with FDA.
Discrepancies between FDA-approved labeling and national Medicare coverage decisions are frequent, particularly for medical devices, where CMS tends to be more restrictive than FDA, researchers reported in Health Affairs. The findings have implications for the parallel review program.